# US 2013/0158011 A1 · Novel compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158011 A1
- Document ID: US20130158011A1
- Status: Published application
- Kind: A1
- Application number: 13/709,330
- Filed: 2012-12-10
- Published: 2013-06-20
- Earliest claimed: 2011-12-14
- Assignees: Boehringer Ingelheim International GmbH
- Inventors: Klaus RUDOLF; Daniel BISCHOFF; Georg DAHMANN; Matthias GRAUERT; Raimund KUELZER; Bernd WELLENZOHN
- Web page: https://patentgrep.com/patent/US20130158011A1

## CPC

- C07D 513/04: Ortho-condensed systems
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 233/64: with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 413/14: containing three or more hetero rings
- C07D 498/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.

## Claims

### Claim 1

A compound of formula I
in which
R1 represents phenyl or
X represents
the group
or a physiologically acceptable salt thereof.

### Claim 2

A compound selected from the group consisting of
or a physiologically acceptable salt thereof.

### Claim 3 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof in admixture with a pharmaceutically acceptable adjuvant, diluent and/or carrier.

### Claim 4 (depends on 1)

A method of treating schizophrenia, schizoaffective disorder and substance induced psychotic disorder; cognitive disorders and dementias including age-associated learning and memory impairments or losses, post stroke dementia, deficits in concentration, mild cognitive impairment, the cognitive dysfunction in Alzheimers disease or the cognitive dysfunction of schizophrenia comprising administering to a patient a therapeutically effective amount of a compound according to claim 1.
